How global events are shaping the pharmaceutical supply chain

In this episode of the EY Health Sciences and Wellness Experience podcast, Derron Stark talks with Olaf Zweig and Famke Krumbmüller.

The speakers talk about the EY report Pharma supply chains of the future and discuss the impact of global events and how a new supply chain model can emerge.

Until recently, the pharma industry has been on the straight path to globalization with integrated supply chains that crossed national borders. A series of geopolitical upheavals though, from the COVID-19 pandemic, to the crisis in Ukraine, caused the industry to re-examine its priorities.

The COVID-19 pandemic and global political tensions highlighted the downsides of a highly integrated supply chain with global dependencies. Politicians started seeking greater guarantees of national and regional supply, rebalancing supply chains to national security and interests.

The discussion then moves to the response of the pharma industry in incorporating regionalization. A hybrid model is emerging that combines globalized thinking with greater self-sufficiency. The key is end-to-end visibility so that companies have a clear line of sight of their supply chain, enabling manufacturing to continue, even in the face of short-term crises, geopolitical tensions, or cyberattacks.

Two positives that emerged from the COVID-19 pandemic were greater collaboration between pharma companies, demonstrated by the vaccine development, and greater dialogue with policy makers. The way forward is the development of a partnership between pharma companies, policy makers, and regulatory bodies to build a new, resilient supply chain model.

Key takeaways:

  • Global tensions and crises have put pressure on pharma companies to re-examine their supply chains.
  • The emerging model is a hybrid one that combines globalization with regionalization.
  • End-to-end visibility is essential, not just with suppliers but with suppliers of suppliers.
  • The supply chain of the future will involve public/private partnerships and greater collaboration between stakeholders.

For your convenience, full text transcript of this podcast is also available. Read the transcript

Presenters

Derron Stark
EY-Parthenon Managing Director, Strategy and Transactions, Ernst & Young LLP
Olaf Zweig
EY-Parthenon Partner, Life Sciences, EY-Parthenon GmbH
Famke Krumbmüller
EY EMEIA Leader, Geostrategic Business Group

Podcast

Episode 09

Duration 23m 55s

In this series

Series overview
(Event List - Manual)

How the path to a sustainable health system unlocks value

In this episode of the EY Health Sciences and Wellness Experience Podcast, Aloha McBride and her guests explore how organizations can reduce climate impact, increase efficiencies and unburden the system.
Podcast

Episode 08

Duration
32m 23s

Presenters

Aloha McBride

EY Global Health Leader

How life sciences companies are measuring their ESG impact

In this episode, Barend van Bergen, EY Global Long-term Value Methodology Leader and Sonja Haut, Head of Impact Valuation for Novartis discuss how companies are measuring their ESG impact.
Podcast

Episode 07

Duration
26m 02s

Presenters

Barend van Bergen

Partner, Strategy and Transactions, EY-Parthenon B.V.

How unlocking the power of data can fuel better health outcomes

In this episode, Pamela Spence, EY Global Health Sciences and Wellness Leader, talks with Nancy Flores, Executive Vice President & Chief Information and Technology Officer for McKesson Corporation.
Podcast

Episode 06

Duration
22m 32s

Presenters

Pamela Spence

EY Global Health Sciences and Wellness Industry Leader and Life Sciences Industry Leader

Nancy Flores

Executive Vice President & Chief Information and Technology Officer for McKesson Corporation

How women are shaping the life sciences industry

In this episode, our speakers share their unique leadership journeys and how they are inspiring the next generation of female leaders in the health sciences and wellness industry.
Podcast

Episode 05

Duration
30m 00s

Presenters

Pamela Spence

EY Global Health Sciences and Wellness Industry Leader and Life Sciences Industry Leader

Trecilla Lobo

SVP, People, BenevolentAI

How data can help redesign the health experience

In this episode of the EY Health Sciences and Wellness Experience Podcast, Pamela Spence discusses the importance of data and how it can help redesign the health experience.
Podcast

Episode 04

Duration
16m 52s

Presenters

Pamela Spence

EY Global Health Sciences and Wellness Industry Leader and Life Sciences Industry Leader

Jackie Hunter

Board Director of Benevolent AI and Chair of the Brainomix Board and the Stevenage Bioscience Park

How shorter clinical trial processes prolong the lives of patients

In this episode, Adlai Goldberg asks Tamie Joeckel, ICON’s Cell and Gene Therapy Global Business Lead, if an increased volume of CGT clinical trials with an accelerated process leads to more life-saving approvals.
Podcast

Episode 03

Duration
29m 13s

Presenters

Tamie Joeckel

Cell and Gene Therapy Global Business Lead, ICON

Adlai Goldberg

EY Global Digital, Social and Commercial Innovation Life Sciences Leader

How digital solutions will help close the health equity gap

In this episode, Adlai Goldberg and two prominent chief medical officers explore and frame the health equity challenges the world is facing today.
Podcast

Episode 02

Duration
32m 49s

Presenters

Dr. David Rhew

MD, Chief Medical Officer, Microsoft

Dr. Yele Aluko

MD, US Health Consulting Executive Director, Ernst & Young LLP

The age of ‘Health Experience’

In this first episode of our EY Health Sciences and Wellness Experience podcast series, we explore the emerging and much needed age of “Health Experience.”
Podcast

Episode 01

Duration
08m 00s

Presenters

Pamela Spence

EY Global Health Sciences and Wellness Industry Leader and Life Sciences Industry Leader